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Summary 
For decades, the hemagglutination-inhibition (HI) assay has been used in epidemiological 
and basic biological studies of influenza viruses. The mechanistic basis of the assay results 
(called titers) is not well understood. The first part of this document describes a biophysical 
model of HI that illuminates the mechanistic basis of and provides the theoretical 
motivation for new ways of interpreting titers. The biophysical model is applicable to other 
serological assays; this fact is illustrated using the neutralization assay. The second part of 
the document describes some new ways of interpreting titers, which involve, among other 
methods, singular value decomposition and probabilistic multidimensional scaling. The 
third part of the document discusses biological and mathematical issues related to the 
determination of the effective dimensionality of titers, and describes an algorithm for 
recovering unavailable titers. 
 
Part 1. Biophysical model of HI 
1.1 Motivation for the model 
Presently, there is a paucity of reliable quantitative information about the biophysical 
determinants of titers. More specifically, there is inadequate knowledge about the manner in 
which both antigenic and non-antigenic parameters contribute to titers. Such knowledge would 
not only allow comparisons of titers obtained under different experimental conditions (e.g., using 
different concentrations of virus and of red cell), it would also enable critical examination of 
existing approaches to interpreting titers. While there are computational methods for inferring 
antigenic relationships from titers [1], to our knowledge there has been only one serious attempt 
[2] at shedding light on the nature of the biophysical interactions that determine these titers. In 
particular, Lanni and Lanni [2] investigated the kinetics of HI and derived mathematical 
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equations for the dynamics of the concentration of, for example, virus-antibody and virus-red 
cell complexes. However, those authors did not derive an equation for the titer. Here, such an 
equation is derived. The approach presented here differs from that of Lanni and Lanni in 
important ways. Firstly, an equilibrium (as opposed to a non equilibrium) chemical kinetic 
framework is used, which is motivated by previous experimental results [3-7] suggesting that the 
virus-antibody and virus-red cell interactions that underlie HI are similar in nature to more 
general enzyme-substrate interactions, and that those HI interactions can attain the equilibrium 
state
1
 on time scales that are typical of the HI assay. Secondly, a collision theory [8] approach is 
employed, allowing virus-antibody and virus-red cell complexes of arbitrary sizes to be 
accounted for, in contrast to the absolute rate theory approach employed by Lanni and Lanni. 
Thirdly, the emphasis is on shedding light on basic aspects of HI; therefore, a smaller number of 
simplifying assumptions are made concerning the nature of HI. 
More specifically, the analyses described here pertain to an HI assay that is designed to 
quantify the titer of virus X relative to antibody-containing serum (or “antiserum”) raised against 
virus Y, denoted 
XYH . The analyses make possible the derivation of a mathematical equation for 
XYH . This mathematical equation is used subsequently to investigate the accuracy of commonly-
used quantitative measures of the antigenic similarity
2
 of virus X to virus Y, namely the 
normalized titer of virus X relative to virus Y-derived antiserum and the Archetti-Horsfall 
measure (denoted AHM) of the antigenic similarity between viruses X and Y. 
                                                 
1
Although the assumption that HI interactions attain equilibrium is consistent with previous experimental results 
(e.g., see [6]), it should be noted that the attainment of equilibrium is dependent on the HI assay conditions (e.g., pH, 
temperature). Moreover, bound influenza viruses can elute from a red cell by cleaving receptors found on the red 
cell surface [9]. This raises the possibility that as influenza viruses continuously bind to and elute from cell surface 
receptors, those receptors could eventually become depleted, thereby rendering red cells non-agglutinable [4,10]. 
However, given that there is on the order of a thousand receptors on each red cell surface [11,12] such loss of 
agglutinability may occur on time scales (respectively temperatures) that are much longer (respectively higher) than 
those typical of HI assays [10]. 
2
The antigenic similarity of virus X to virus Y is defined as the degree to which antibodies raised against virus Y 
neutralize virus X. Note that antigenic similarity, as defined here, is not necessarily symmetric. 
3 
 
 
1.2. Preliminaries 
The main steps involved in determining the titer of virus X relative to virus Y-derived 
antiserum are as follows (e.g., see [13]): Firstly, virus X is propagated in chicken eggs (or in cell 
culture), yielding a concentrated solution of the virus. Serial 2-fold dilutions of the virus solution 
are made and a fixed volume of each diluted solution is mixed with a fixed amount of red cells 
(see Figure S1). The virus-red cell mixtures are incubated for a specified amount of time (e.g., 1 
hour) and then examined for the occurrence of agglutination, which is characterized by the 
absence of a “button” at the bottom of the experimental vessel. The highest dilution of the virus 
solution that elicits marked agglutination of red cells is called the hemagglutination endpoint. 
The corresponding amount of virus is denoted by 1 hemagglutinating unit. After determining the 
hemagglutinating unit of virus X, 10 serial 2-fold dilutions of antiserum obtained from organisms 
(e.g., ferrets) infected by virus Y are made. A fixed volume of each diluted antiserum is mixed 
with an equal volume of a solution containing 4 hemagglutinating units of virus X. To this 
antibody-virus mixture is then added a fixed amount of red cells (the same as the amount of red 
cells used in determining the hemagglutinating unit, as mentioned above). The 10 antibody-
virus-red cell mixtures thus obtained are incubated, and checked subsequently for the occurrence 
of agglutination. The titer is defined as the reciprocal of the highest dilution of antiserum that 
inhibits marked agglutination of the red cells. 
4 
 
 
Figure 1. Schematic illustration of the main steps of the HI assay. Antisera taken from experimentally 
infected ferrets, or from other sources, are diluted serially in microtiter plates (test tubes are shown for 
ease of presentation). The virus under investigation is grown in cell culture or in hen‟s eggs to produce a 
concentrated virus solution. A standardized amount of the virus (see text) is then added to the diluted 
antisera followed by addition of a suspension of red cells. The resulting mixtures are incubated for a fixed 
amount of time (e.g., 1 hour). Following incubation, the mixtures are examined for the presence of 
hemagglutination, characterized by the absence of a button at the bottom of the plate. The HI titer is 
defined as the reciprocal of the highest dilution of antiserum that inhibits agglutination. In the example 
shown, the HI titer is given by A0/ As=H, where As is the concentration of antibodies found in the 1:H 
dilution and A0 is the concentration of antibodies found in undiluted antiserum. 
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Note that antisera generally contain different populations of antibodies each of which 
may have a different affinity for the target virus. The measured affinity of antisera for a virus is 
the average of the affinities of these different antibody populations. In addition, note that the HI 
assay protocol is similar to protocols for other serological assays, including the more sensitive 
neutralization assay [13]. The main difference between the protocols for the HI and 
neutralization assays is that in the latter assay samples taken from equilibrium antibody-virus 
mixtures are incubated with susceptible target cells (e.g., Mardin-Darby canine kidney cells), and 
the neutralization titer is defined as the reciprocal of the maximum dilution of antiserum that 
inhibits infection in at least 50% of the antibody-virus-cell mixtures. 
In the following, the various steps of the HI assay described above are explicitly 
modeled. First, the kinetics of agglutination of red cells by influenza viruses are analyzed, 
followed by the kinetics of antibody-mediated inhibition of agglutination. Connections to the 
neutralization assay are subsequently discussed. 
 
1.3. Agglutination of red cells by influenza viruses 
The surface of each influenza virus contains numerous hemagglutinin (HA) molecules 
[9,14]. Each HA molecule contains a specific site (also called a receptor binding site) that can 
interact with and bind to a cognate sialic acid-containing receptor found on the surface of a red 
cell. Typically, multiple receptor binding sites found on the surface of a given virus bind to 
distinct cell surface receptors found on the same red cell surface; each virus-red cell “bond” is 
multivalent
3
. This multivalency is necessary in order to ensure the stability of a virus-red cell 
bond since individual receptor binding site-cell surface receptor bonds are very weak, having 
equilibrium dissociation constants that are on the order of a millimolar [15]. Let a denote the 
maximum number of red cells that can be bound simultaneously by the same influenza virus (i.e., 
                                                 
3
 The formation of the first receptor binding site-cell surface receptor bond between a virus and a red cell brings 
adjacent receptor binding sites (found on the surface of the virus) and cell surface receptors (found on the surface of 
the red cell) closer to each other and, hence, facilitates the formation of additional receptor binding site-cell surface 
receptor bonds. Accordingly, the rate of formation of a multivalent virus-red cell bond would be given 
approximately by the rate of formation of the first receptor binding site-cell surface receptor bond. 
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the “effective” number of receptor binding sites)4 and let b denote the maximum number of 
influenza viruses that can bind simultaneously to the same red cell (i.e., the “effective” number 
of cell surface receptors). Previous experimental results suggest that a≈2 [16]. Meanwhile, for 
chicken red cells, experimental estimates of b range from 830 to 1660 [12]. Higher estimates of b 
(up to 5,000) have been obtained, using influenza B viruses [11]. 
As noted earlier, the titer is determined experimentally by observing the pattern of 
agglutination occurring in 10 mixtures, each containing fixed amounts of virus and of red cell 
and differing amounts of antibody-containing antiserum. Consider the interactions between virus 
and red cell occurring in the ith mixture, 101  i . Let V denote the molar concentration of virus 
particles found in this mixture, B the concentration of red cells, iA  the concentration of 
antibodies, and ix  the concentration of virus-red cell bonds found in the ith virus-antibody-red 
cell mixture. The collision frequency BVZ  between virus and red cell can be estimated from first 
principles [8]. During a particular collision between virus and red cell the probability that a 
receptor binding site of the virus is free is given by   aVxaV i , while the probability that a 
cell surface receptor of the red cell is unoccupied is given by   bBxbB i . Now, let   denote 
the probability that during the collision a free receptor binding site will make contact with an 
unoccupied cell surface receptor, in the proper orientation (i.e., such that steric hindrance is 
overcome). Based on the Maxwell-Boltzmann distribution of the kinetic energies of the colliding 
particles a fraction,  RTEaexp , of such properly oriented collisions will result in the 
formation of a virus-red cell bond, where aE  is the activation energy for virus-red cell bond 
formation. On the other hand, virus-red cell bonds will dissociate at the rate  RTEf d /exp  , 
where dE  is the activation energy for dissociation of a virus-red cell bond and f is a pre-
exponential factor (this dissociation rate depends on the activity of the influenza viral 
                                                 
4
 The significantly larger size of a red cell compared to that of an influenza virus - the volume of a spherical 
influenza virus particle, with a diameter of  m110  [15], is 3410 m , while that of a chicken red cell is estimated to 
be 3210 m  [16] - would limit severely the number of red cells that can be bound simultaneously by the same 
influenza virus.  
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neuraminidase protein). Therefore, ignoring, for now, the presence of antibodies, the dynamics 
of the concentration of virus-red cell bonds is given by
5
: 
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where  RTEZK aBV /1    and  RTEfK d exp2 . Observe that a=2 in (S1). 
Let e
ix  denote the equilibrium concentration of virus-red cell bonds found in the ith 
virus-antibody-red cell mixture. At equilibrium, the concentration of doubly-bound viruses is 
  Vxei 4
2
 and the fraction of agglutinated red cells (i.e., the fraction of red cells bound by a 
doubly-bound virus) is given by: 
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1.4. Antibody-mediated inhibition of agglutination 
Antibodies recognize and bind to specific antigenic sites of HA molecules found on the 
influenza viral surface. Theoretical interpretations [5,17] of experimental data on influenza virus-
antibody interactions suggest that there are ~2000 antigenic sites per influenza virus. The 
mechanism by which antibodies neutralize
6
 influenza viruses and, hence, inhibit red cell-
agglutination [18] is not well understood. The physical closeness of antigenic sites to receptor 
binding sites and the relatively large sizes of antibodies suggest that bound antibodies may 
neutralize influenza viruses by occluding receptor binding sites, thereby preventing those sites 
from binding to cell surface receptors [19,20]. This “occlusion” mechanism is supported by the 
                                                 
5
 A virus can only form one virus-red cell bond with a particular red cell. Since the number of red cells is typically 
very large (see arguments presented later in the text) it is not necessary to account explicitly for the (negligible) 
probability that the virus and red cell under consideration are not already bound to each other.  
6
 When we talk of neutralization, we are referring specifically to neutralization of infectivity, which is a sufficient, 
although not a necessary, condition for inhibition of hemagglutination [19].  
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results of previous experimental studies [7,21,22] on antibody-mediated neutralization of 
influenza viruses. Those experimental results suggest that the fraction of neutralized influenza 
viruses increases with the average number of bound antibodies per virus in a sigmoidal manner. 
The occlusion mechanism described above could be relevant for the neutralization of a number 
of other viruses, including the human immunodeficiency virus (reviewed in [20]). 
Note that in spite of the high average number of antibodies that were bound to each 
neutralized influenza virus at the neutralization endpoint [7,20,21], the kinetics of neutralization 
was apparently first-order [7]. This led to the hypothesis that neutralization may require that a 
single antibody binds to an antigenic site that is “critical” or “neutralization-relevant” [7]. 
According to this hypothesized “critical sites” mechanism, when an antibody binds to a critical 
antigenic site it may elicit conformational (and other types of) changes to the entire viral surface, 
and those changes may render receptor binding sites incapable of binding to cell surface 
receptors [20]. However, there is no documented evidence of such changes to the influenza viral 
surface induced by antibody binding. Moreover, as has been noted on many occasions (e.g., 
[23]), the observed pseudo-first-order kinetics of neutralization could be due to the fact that 
antibodies were used in excess over influenza viruses in the cited experiments. In light of the 
paucity of supporting experimental evidence, the critical sites mechanism will not be considered 
further. 
The occlusion mechanism of antibody-mediated neutralization of influenza viruses 
suggests that the probability of neutralization could be described mathematically by the 
following equation: 
 
hh
h
y
y
yp



,          (S3) 
where y  is the average number of bound antibodies per virus,   is the average number of bound 
antibodies per virus at 50% neutralization, and h is the Hill coefficient. For the HC10 antibody 
used in [7] the Hill coefficient is 3h  [24]. 
If iy  denotes the concentration of virus-antibody bonds found in the ith antibody-virus-
red cell mixture, then the average number of bound antibodies per virus is given by Vyi . 
Therefore, substituting Vyi  for y  in (S3) gives the probability that a particular virus is 
neutralized: 
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Modifying eqn. (S1) to account for the fact that only un-neutralized viruses can bind red 
cells gives the following equation for the dynamics of the concentration of virus-red cell bonds: 
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At equilibrium, the concentration of virus-red cell bonds found in the ith virus-antibody-red cell 
mixture is given by:  
  
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where      heiaa
h
ybVKbBKbV 222    and 21 KKK a   is the equilibrium association 
constant for virus-red cell binding, that is, the affinity of virus for red cell. 
A corresponding equation for the dynamics of the concentration of virus-antibody bonds 
can be derived using the same principles as those outlined above. Briefly, viruses will collide 
with antibodies with frequency AVZ  [8]. Let n denotes the number of antigenic sites per virus. 
The probability that an antigenic site is unoccupied is given by   nVynV i . Meanwhile, the 
probability that an antibody is free is given by   iii AyA  . As before, let ~  denote the 
probability that during a given collision between virus and antibody the antibody will make 
contact with a free antigenic site of the virus in the proper orientation. A fraction,  RTEa
~
exp  , 
of such properly oriented collisions will result in the formation of a virus-antibody bond, where 
aE
~
 is the activation energy for virus-antibody bond formation. On the other hand, virus-antibody 
bonds will dissociate at the rate  RTEf d /
~
exp
~
 , where dE
~
 is the activation energy for 
dissociation of a virus-antibody bond and f
~
 is a pre-exponential factor. Therefore, the dynamics 
of the concentration of virus-antibody bonds is given by: 
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where  RTEZK aAV /
~
exp~
~
1    and  RTEfK d
~
exp
~~
2  . 
Due to the large size of a red cell, each virus-red cell bond would occlude a certain 
number of antigenic sites on the bound virus. Let us assume that, as in the case of viral 
neutralization by antibodies, the probability that a given antigenic site is occluded by red cells is 
an increasing, sigmoidal function of the average occupancy of receptor binding sites, with a 
maximal probability of 10,  , and a half-maximal average occupancy of 1: 
i
ii
xV
x
V
x
p






 
.          (S8) 
Using (S7) and (S8), the equation for the dynamics of the concentration of virus-antibody 
bonds becomes: 
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At equilibrium, the concentration of virus-antibody bonds found in the ith virus-antibody-red cell 
mixture is given by: 
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where        eieiaeia nxxVKnVxVAK   1
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11
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0  and 21
~~~
KKKa   is the 
equilibrium association constant for virus-antibody binding, that is, the affinity of antibody for 
virus. 
 
1.5. Mathematical definition of the titer 
As noted earlier, the titer of virus X relative to antiserum containing antibodies raised 
against virus Y (i.e., 
XYH ) is defined as the reciprocal of the highest dilution of the antiserum 
that inhibits marked agglutination of red cells by virus X; that is, the ratio of the concentration of 
antibodies found in undiluted antiserum to the minimum concentration of antibodies that inhibits 
marked agglutination (see Figure S1). If we let l, 10  l , denote a threshold value indicating 
marked agglutination (e.g., 70% agglutination), then 
XYH  is defined mathematically as follows:  
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where 0A  is the concentration of antibodies found in undiluted antiserum and e
ix
f  is given by 
(S2).  
 A straightforward approach to obtaining a mathematical expression for 
XYH  is to solve 
(S5) and (S10) for e
ix ; set lBVx
e
i 2  and solve for iA ; and set  i
XY AAH min0 . However, 
this approach is analytically intractable. Therefore, the following approach is used to obtain an 
approximate expression for 
XYH : substituting for e
iy  in 0dtdxi  and solving for iA  gives: 
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Now, substituting lBVxei 2  into (S12) gives:  
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It follows from (S11) and (S14) that the value of iA  that satisfies  lBVxA eii 2:min   is 
given approximately by:        ahhah KnlBVVVlBVVnKV
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Note that (S16) is an approximation because the expression for  lBVxA eii 2:min   is 
also an approximation. It is important to bear in mind that the accuracy of the experimentally 
measured value of 
XYH  depends crucially on the dilution factor used in the HI assay. For greater 
accuracy the dilution factor should be very close to 1. However, this is impractical for many 
reasons, including the fact that an astronomical number of antiserum dilutions may be required in 
order for the HI assay endpoint to be reached. 
It is worth drawing attention to an interesting connection between the general 
mathematical form of the HI equation derived above and the mathematical form of the equation 
for the neutralization titer. As discussed earlier, the neutralization titer is defined as the 
reciprocal of the maximum dilution of antiserum raised against virus Y (or the minimum 
concentration of antibodies) that prevents infection of susceptible cells by virus X in at least 50% 
of cell cultures inoculated with a sample taken from a mixture of the antiserum and virus X [11]. 
Let c be the minimum concentration of free or un-neutralized particles of virus X required to 
infect at least one cell in 50% of inoculated cell cultures. The dissociation of bonds between 
antibodies and virus X following inoculation into cell cultures would occur very infrequently 
since the concentration of virus particles used (and, hence, the maximum possible concentration 
of antibody-virus bonds) is very low [11], while 
2
~
K , the dissociation rate of an antibody-virus 
bond, is typically small. Therefore, viruses that are neutralized prior to inoculation could remain 
in that state, while un-neutralized viruses would mostly account for subsequent infection of 
susceptible cells. The neutralization titer can be defined as: 
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0 ,        (S17) 
where p, the equilibrium fraction of neutralized viruses, is given by (4), and r is the ratio of 
infectious to non-infectious viral particles (for influenza viruses, r~.02 [14]).  
It can be seen from both (S4) and (S7) that  rVcp 1  implies: 
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Using (17) and (18) we find that the neutralization titer is given by the expression:  
   

nVnK
AK
N
a
aXY
~
~
0 ,         (S20) 
which has a similar mathematical form as (S16). 
 
1.6. Some remarks on the derived HI equation 
 Recall that in (S16), which quantifies the titer of virus Y relative to virus X-derived 
antiserum, the parameter V denotes the concentration of virus X, R the concentration of red cells 
(which is typically standardized across HI assays), aK  the avidity of virus X for red cell, 0A  the 
concentration of antibodies found in virus Y-derived antiserum, and aK
~
 the affinity of those 
antibodies for virus X. For clarity, super-scripts will be used to further specify these parameters; 
for example, YA0  will be used to denote the concentration of antibodies found in virus Y-derived 
antiserum and 
XY
aK
~
 to denote the affinity of those antibodies for virus X. In the following, Eqn. 
(S16) is used to assess the accuracy of two commonly-used HI-based methods of quantifying the 
antigenic difference between influenza viruses. First, some observations on the mathematical 
form of (S16) are in order. Eqn. (S16) makes a number of parameter-free predictions that are 
intuitive and also consistent with empirical data. Firstly, as expected (e.g., see Tables I & II in 
[25]), the equation predicts that the titer of virus X relative to virus Y-derived antiserum, 
XYH , 
increases linearly  with the concentration of antibodies found in the antiserum, YA0 , and it also 
increases with the affinity of those antibodies for virus Y, 
XY
aK
~
, and with the agglutination 
threshold, l. 
On the other hand, 
XYH  is predicted to decrease with the concentration of virus X, XV , 
with the avidity of virus X for red cell, X
aK , and also with the average number of antibodies that 
must be bound to each particle of virus X in order to neutralize it with a probability of 50% (i.e., 
 ). Indeed, the predicted inverse correlation between XYH  and X
aK  is consistent with 
experimental data showing that the titer decreases as the strength of virus-red cell interactions 
increases, due to passage of virus in eggs [4]. It is also worth noting that eqn. (S16) predicts that 
XYH  would be approximately invariant to changes in 
XY
aK
~
 if 
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       XYahhXXX KnlBVVVlBVVnr
~
2212 /1/1   .    (S21) 
Meanwhile, 
XYH  would increase approximately linearly with 
XY
aK
~
 if r>> 
XY
aK
~
, and it would 
increase with 
XY
aK
~
 in a sigmoidal manner for intermediate values of r. Therefore, the sensitivity 
of the HI assay to antigenic differences between influenza viruses could be influenced by the 
value of r. Below, possible ranges for r are estimated using reasonable values of relevant 
experimental parameters, providing insight into the potential sensitivity of the HI assay. 
Consider the virus-red cell mixture that corresponds to the hemagglutination endpoint 
(see above) and denote by 
XV
~
 the concentration of virus particles (i.e., 1 hemagglutinating unit) 
found in this mixture and by R
~
 the concentration of red cells. The virus-red cell mixture 
contains 0.5ml of a .5% standardized suspension of red cells in a 1ml solution [26]. In the case of 
chicken red cells, 0.5ml of a .5% standardized chicken red cell suspension contains 7103  red 
cells [27]. In addition, for influenza viruses that are pre-adapted to red cells (i.e., by means of 
egg passage), the virus-red cell mixture typically [28,29] contains approximately as many viruses 
as red cells
7
. In other words, the concentration of virus particles found in the virus-red cell 
mixture is given approximately by     MV X 142337 1051002.610103~  , suggesting 
that the concentration of virus particles used in the HI assay is MVV
XX 13102
~
4  .  
On the other hand, 
XY
aK
~
 was found to range from 6106  to 19101  M  [30], for 
monoclonal antibodies targeted to all five HA epitopes of influenza viruses (and their antibody 
escape mutants) belonging to the H1N1 and H3N2 subtypes; and from 8107  to 19102  M  
[31], for monoclonal antibodies targeted to three HA epitopes of an influenza virus belonging to 
                                                 
7
 At the hemagglutination endpoint the ratio of the number of red cell-associated influenza viruses to the number of 
red cells is estimated to be ~1 [29,32]. Since virus-red cell bonds are extremely stable [30], the vast majority of 
viruses found at the hemagglutination endpoint would be associated with red cells, hence the conclusion that 1 
hemagglutinating unit contains approximately the same number of viruses as it does red cells. 
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the H7N1 subtype
8
. Using 
19101
~  MK XYa , MV
X 13101  , n=2000 [18], and h=3 [24], it 
can readily be shown that r>> 
XY
aK
~
 for a wide range of values of both   and h/1 . Therefore, 
the HI assay could be fairly sensitive to antigenic differences between influenza viruses. Indeed, 
the HI assay can detect immunologically consequential point mutations to individual influenza 
virus HA epitopes much more accurately than sophisticated methods such as the enzyme-linked 
immunosorbent assay [30]. 
The foregoing discussion suggests that it is reasonable to approximate 
XYH  by: 
   
 XXh
hhXXXYXY
aXY
lBVVn
nlBVVVAK
H
2
221
~
/1
/1/1
0





.     (S22) 
Eqn. (S22) predicts that 
XYH  can be written as the product of 
XY
a
YXY KAC
~
0 , which depends on 
the antigenic difference between viruses X and Y, and 
      XXhhXXXX lBVVnnlBVVVJ 2221 /1/1   , which depends on such 
non-antigenic parameters as the amount of virus X and the avidity of virus X for red cell: 
XXY
a
YXY JKAH
~
0           (S23) 
This suggests that a natural way to decouple the antigenic and non-antigenic contributions to 
XYH  is to transform the titer logarithmically, since the log-transformed titer is additive in the 
effects of antigenic and non-antigenic variables. 
 
1.7. Accuracy of existing measures of antigenic difference 
The normalized titer (NHT) of virus X relative to virus Y-derived antiserum is the most 
commonly-used measure of the antigenic similarity of virus X to virus Y (e.g., [13,33]). More 
specifically, NHT is defined as: 
YYY
XXY
YY
XY
XY
JC
JC
H
H
NHT  .         (S24) 
                                                 
8
 The (polyclonal) antibodies found in antisera are heterogeneous with respect to their avidity for virus and the 
average affinity of those antibodies for a given virus strain could be lower than the affinity of a monoclonal antibody 
targeted to a dominant HA epitope of that virus strain. 
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Observe that for a given amount of antigenic difference between X and Y, 
XYH  would 
increase with the amount of antibodies found in antisera, which varies with the ability of virus Y 
to induce antibodies in infected hosts as well as on the immune status of those hosts [34]. 
Normalizing 
XYH  by 
YYH  is useful because it helps to control for the potential confounding 
effect of the amount of antibodies on the estimation of antigenic differences. Unfortunately, as 
indicated by the presence of both XJ  and YJ  in (S24), the normalized titer still depends on non-
antigenic variables, which may confound estimates of the antigenic difference between viruses X 
and Y. For example, if XJ  is much smaller than YJ  (as may occur if virus Y has much lower 
avidity for red cell than virus X), then the normalized titer may predict, incorrectly, that virus X is 
antigenically very different from virus Y even if both viruses are antigenically similar. 
In contrast to the normalized titer, the AHM of the antigenic difference between viruses X 
and Y is defined only for cases when both homologous and heterologous titers are available for 
the two viruses. More precisely, the AHM is given by [36,37]: 
2/12/1













YYXX
YXXY
XX
YX
YY
XY
YXXY
CC
CC
H
H
H
H
AHMAHM .     (S25) 
Eqn. (S25) predicts that the AHM is approximately independent of the non-antigenic variables 
represented by both XJ  and YJ . In other words, the AHM is influenced by non antigenic 
variables to a lesser degree than is the normalized titer; the AHM could afford a more reliable 
measure of antigenic differences between viruses than the normalized titer. This is consistent 
with results presented in [38]. The above results suggest that AHM should be preferred over the 
normalized titer, whenever possible. This could be particularly beneficial when there is 
significant variation in the non-antigenic properties of the viruses being analyzed. 
 
Part 2. Some applications of the biophysical model 
2.1. Singular value decomposition (SVD) of titers 
In mathematical terms, an HI table H has the form of an m by n matrix, with m the 
number of viruses represented in the table and n the number of antisera. Each entry 
XYH  in H 
represents the titer of virus X relative antiserum raised against virus Y. As shown above, the 
logarithm of the normalized titer ( YYXY HH titerNormalized ) depends additively on noise and 
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other non-antigenic contributions. The log-transformed normalized titers corresponding to a 
particular virus form a vector defined in a space of dimensionality less than or equal to n. Basis 
vectors for this space can be determined by means of SVD: 
TVSUH  ,          (S26) 
where U is an m by m column orthonormal matrix (i.e., 
m
T IUU  ), S an m by n diagonal 
matrix of n singular values, nii ,,1,  , and V an n by n column orthonormal matrix. The 
superscript T denotes matrix transpose, while “*” denotes matrix multiplication. The columns of 
U and V correspond to the eigenvectors of THH   and HH
T  , respectively, while the ith 
singular value in S corresponds to the positive square root of the eigenvalue associated with the 
eigenvector found in the ith column of both U and V.  
The eigenvectors found in V are orthonormal superpositions of the titers found in H. In 
other words, the eigenvectors represent orthogonal subsets of the variation (denoted 
“eigenfactors”) found in titers. For illustration, consider two factors that are known to contribute 
to the titer of virus X relative to antiserum raised against virus Y: the affinity of the antibodies for 
virus X and the avidity of virus X for red cells. Since these factors are, to a reasonable 
approximation, mutually independent their contributions to titers will be captured by different 
eigenfactors; this suggests a novel approach to decoupling the contributions of the mentioned 
factors and, therefore, to improving predictions of antigenic similarity. 
The relative contribution of (or the fraction of the variation in titers that is explained by) 
the ith eigenfactor is given by: 
 
n
j jii
p
1
22  .          (S27) 
The fraction of the variation explained by a given subset of eigenfactors is the sum of the 
fraction of the variation explained by the individual eigenfactors. To quantify antigenic 
differences between viruses, the matrix H of titers is mapped onto the standard coordinate system 
in 
nR  by a change of basis: TT HV  . Those eigenfactors that are deemed to reflect measurement 
noise (e.g., eigenfactors that make a very small relative contribution to titers, as indicated by ip ) 
are filtered out by setting the viral coordinates associated with those eigenfactors to zero. The 
antigenic difference (called eigendistance) between a given pair of viruses is defined as the 
Euclidean distance between the coordinates of those viruses, in the subspace spanned by the 
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unfiltered eigenfactors. Broad-scale patterns of antigenic similarities among viruses are 
elucidated via computational clustering of the viral coordinates. If the number of unfiltered 
eigenfactors is small (i.e., less than or equal to 3), then the coordinates of viruses can be plotted 
in order to visualize the elucidated patterns. Moreover, specific subsets of the unfiltered 
eigenfactors can be endowed with biological significance, whenever possible, on the basis of 
known attributes of viruses that correlate with those eigenfactors. 
In the following, two examples are used to illustrate how the above SVD method can 
enable the delineation of antigenically relevant variation found in titers. First, the method was 
applied to tables of titers for H3N2 viruses [38]. For each table, the eigenfactors were computed 
and all subsets of those eigenfactors of sizes ranging from 2 to 5 were determined. 
Eigendistances between pairs of viruses were subsequently computed for each eigenfactor subset 
(see above). The amount of variation explained by each eigenfactors subset was also determined 
(see above). The antigenic relevance of the variation explained by a particular eigenfactor subset 
was quantified as the average correlation between eigendistances computed using that subset and 
the corresponding AHM measure of the antigenic similarity between pairs of viruses. Figure S2a 
shows a plot of the average correlation versus the explained variation for all eigenfactor subsets 
and all analyzed tables. The results show that different subsets of eigenfactors can accurately 
predict AHM, irrespective of the amount of variation they explain (Figure S2a). An interesting 
feature of the results is that the ability to predict AHM increases as the explained variation also 
increases from 0% to ~40%, and then it drops sharply only to increase again as the explained 
variation increases above ~60%. The location of the sharp drop corresponds approximately to the 
average amount of variation explained by the first eigenfactor. This suggests that the variation 
explained by the first eigenfactor may not be antigenically relevant, in spite of the fact that it is 
the dominant eigenfactor. In contrast to the above results obtained using un-centered titers, when 
the titers from each table are mean-centered prior to their analysis, the relationship between the 
explained variation and the ability to predict AHM becomes linear (Figure S2b), suggesting that 
mean-centering may have minimized the effect of the first eigenfactor. This example illustrates 
the potential of the above method to provide insight into the nature of the variation found in 
titers. 
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Figure S2. Predictive accuracy of subsets of eigenfactors with respect to the AHM measure of antigenic 
similarity. Tables of titers from [38] that contain 5 or more antisera for H3N2 viruses were analyzed. The 
tables were either un-centered (a) or row-centred (b) prior to their analysis. The eigenfactors for each 
table were computed and the viruses from each table were subsequently mapped onto subspaces spanned 
by each of the 26 possible subsets of the first 5 eigenfactors (excluding subsets of size 1). [The 
eigenfactors were ranked in decreasing order of the amount of variation explained by each]. For each 
table and for each subset of eigenfactors, the AHM measure of the antigenic distance between pairs of 
viruses as well as the eigendistances between those pairs of viruses (see above). The correlation 
coefficient between the negative log (base 2) of AHM and the eigendistances was plotted against the 
explained variation for all subsets of eigenfactors. 
 
In addition, the SVD method was applied to a row- and column-centered version of a 
table of titers for 21 viruses belonging to three antigenic subtypes (H1N1, H2N2, and H3N2) of 
influenza viruses. The goal of this particular application was to determine the effect of mean-
centering titers on the ability to recover known antigenic relationships between the viruses under 
consideration. A visual map of the viruses was constructed (Figure S3a), as described above. The 
map allowed the three natural antigenic clusters of the viruses to be accurately recovered using 
the k-means clustering algorithm [39]. In contrast, when the method was applied to versions of 
the above table that were either un-centered (Fig. S4b), only row-centered (Fig. S4c), or only 
column-centered (Fig. S3d), the resulting visual maps did not enable accurate recovery of the 
natural antigenic clusters of the viruses, suggesting that the proposed mean-centering procedure 
may be useful indeed. Note that the centered, normalized titers require at least two dimensions to 
be plotted. Some factors that may influence the number of required dimensions are discussed in 
Part 3 of this document. 
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Figure S3. Antigenic maps of H1N1 (circles), H2N2 (squares), and H3N2 (diamonds) influenza viruses. 
The maps were constructed as described above, using a table of titers (H369001) published in [38]. The 
table was either un-centered, row-centered, column-centered, or row- and column-centered before it was 
used. Three viral antigenic clusters (colored in red, blue, and black, respectively) were obtained by 
applying the k-means clustering algorithm [39] to viral coordinates taken from each map. Virus notation: 
AA57 AA/23/57, BE42 Bellamy/42, CA46 Cam/46, FM47 FM/1/47, GF51 GFM/51, HK68 Hong 
Kong/1/68, JP62 Japan/170/62, ME35 Melbourne/35, NS69 New South Wales/5/69, NT68 Northern 
Territory/60/68, NZ62 New Zealand/11/62, NZ64 New Zealand/14/64, PR34 Puerto Rico/8/34, PR64 
Puerto Rico/1/64, SA57 South Australia/12/57, SI57 Singapore/57, SW31 Swine/31, SY64 Sydney/2/64, 
TI64 A/Taiwan/64, VC68 Victoria/4/68, WS33 WSE/33. 
 
 A general approach to SVD suitable for HI tables with missing data: The SVD projection of 
a mean-centered HI table H, which is given by TT HV * , yields the transpose of the matrix of 
principal components of H, denoted here by the qm  matrix W, nq  . Indeed, the SVD 
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projection of H is recovered exactly, in the zero-noise limit, as the maximum likelihood solution 
of the following statistical model [40]: 
 XWH * ,          (S28) 
where TVX   is the nq  matrix of eigenfactors, and   2,0~   denotes isotropic, 
multidimensional Gaussian noise. It is often convenient to ensure the orthogonality of 
eigenfactors by requiring that   ,0~X . It follows that   2*,0~ TWWH . 
The maximum likelihood estimates of W and 2  are given by [40]: 
  RUW qqML **
2/12   and        (S29) 



m
qj
jML
qm 1
2 1  ,          (S30) 
respectively, where the columns of 
qU  are the first mq   eigenvectors of 
THH * , whose 
eigenvalues 
q ,,1   are found in the diagonal matrix q . R is a rotation matrix, which, for 
convenience, can be set to the identity matrix. In our applications to HI data, we found that 
0~j  for nj  , so that both the deterministic and probabilistic SVD projections are essentially 
equivalent in this case. 
 In many cases (e.g., when the viruses being compared are antigenically either very 
similar or very divergent) the titer is either too small or too large than can be measured reliably 
by the HI assay. In such cases, the titer in question is reported as a threshold value. HI tables 
containing such threshold (or missing) titers cannot be decomposed by using the SVD approach 
described in the previous section since THH *  is not well-defined in this case. Tipping and 
Bishop [40] proposed an expectation maximization algorithm for dealing with such missing data, 
but their approach requires making certain assumptions about the nature of the missing data that 
are untenable in the case of HI data. A better alternative is the alternating regression approach 
used by Liu and co-workers [41] to analyze microarray data. This approach is modified here in 
order to account for threshold titers. 
 Each entry ijH  of a mean-centered HI table H is expressed as: 
ijjiij XWH  ** * ,          (S32) 
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where *iW  denotes the ith row of the matrix W of principal components of H and jX*  denotes 
the jth column of the rotation matrix X. *iW  and jX*  are solved for by the following alternating 
regression procedure [41]: 
1. Initialize X (here the initial value of X is drawn from   ,0 ). 
2. Use X to solve for W. 
3. Use W (obtained in step 2) to solve for X. 
4. Repeat steps 2 and 3 until convergence of H-W*X. 
Note that an exact solution can be obtained in steps 2 and 3 of the above algorithm. The columns 
of the final solution for X may not be mutually orthogonal, that is, the condition   ,0~X  may 
not be satisfied. Therefore, the matrices W and X are transformed to ensure that this condition is 
satisfied: 
 XWH
~
*
~
,           (S33) 
where   12/1*~   TGGWW ,   XGGX T   2/1~ , and TT GGXX * . It is 
clearly seen that   ,0~~X : 
 
   
   
    IGGGGGG
GGXXGG
XGGXGGXX
TTTT
TTTT
TTTT






2/12/1
2/12/1
2/12/1
*
**
~~
     (S34) 
For a threshold titer ijH  the expression   jiijij XWHHsign ** *exp   is minimized, 
where 0  and  
ijHsign  equals +1, if ijH  is the lower bound of the titer, and -1, if ijH  is the 
upper-bound of the titer. This expression was chosen to ensure that the error associated with 
ijH  
makes an appreciable contribution to the total error   [see Eqn. (S33)] only when the threshold 
condition represented by ijH  is violated. 
 
2.2. Probabilistic multidimensional scaling (MDS) of antigenic differences 
 Given a collection of HI tables, SVD is used to compute antigenic differences (or 
eigendistances) between the viruses found in each table (see above). These eigendistances are 
subsequently embedded in a common, reduced space, of dimensionality k, by means of 
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probabilistic MDS [42]. In order to accomplish this, an explicit model for the noise structure of 
eigendistances is assumed. The distribution of the noise associated with eigendistances can be 
reasonably approximated by the log-normal distribution (e.g., [43]), which captures the fact that 
(i) titers are always non-negative, and (ii) they depend on multiplicative stochastic processes, for 
example, resulting from the serial dilution of sera. In other words, the likelihood of the 
eigendistances found in the tth HI table under consideration can be approximated by:  
   















 
 

ijt
ji
tji
ji
N
t
N
tt
D
XX
XXkXDp tt
**2
2
,
1
**
2/12
ln
2
1
exp2,,

 ,  (S35) 
where tD  denotes a matrix of eigendistances between the viruses found in the tth table, 
2
t  the 
variance of those eigendistances, tN  the number of eigendistances found in tD ,   the 
Euclidean norm, and X a matrix of viral coordinates. The matrix X has dimensions km , where 
m is the total number of distinct viruses found in the tables under consideration. 
 The maximum likelihood estimate (mle) for 
2
t  is given by tt NS , where 
 






 

ji ijt
ji
t
D
XX
S
,
**2log .         (S36) 
Substituting the mle for 
2
t  into (S35) gives the joint log-likelihood function (excluding terms 
that do not depend on parameters) of eigendistances from all the tables under consideration: 
  
t
tt
t
k NS
N
L log1log
2
log ,       (S37) 
where the subscript emphasizes the dependence on k. It follows from (4) that kL  attains its 
maximum value, kLˆ , when t tt SN log  is minimized with respect to X; this also yields the mle 
for X, which is subsequently mean-centered and transformed to ensure that its columns are 
mutually orthogonal
9
. kLˆ  is used to estimate the optimal value of k, defined as the value of k that 
                                                 
9
 If we transform X by setting UXX  , where TUSU   is the SVD of XX T  , then the columns of X  will 
become mutually orthogonal: SXX T  . 
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minimizes the Bayesian information criterion [44]:     t tk NmkL logˆ 21 . Note that 
t tt SN log  is minimized using the method of simulated annealing [45], since this method can 
circumvent the local minima that are characteristic of the solution of space of this type of 
nonlinear optimization problem. 
 
Confidence regions for the MDS coordinates of viruses:  After obtaining the mle, 0Xˆ , for the 
km matrix of viral coordinates from the MDS of eigendistances, 95% confidence regions for 
these coordinates are computed as follows: 100 bootstrap copies of the eigendistances are 
created, and the mle, iXˆ , for viral coordinates consistent with the ith bootstrap copy, 1001  i , 
is computed. Each iXˆ  is then mean-centered and transformed (via a Procrustrean fit) so that its 
Euclidean distance to 0Xˆ  is minimized. Specifically, the following transformation is applied to 
each iXˆ  [46]: 
    TiTiiTTii UVXXXXUVXX  ˆˆˆtraceˆˆtraceˆ 0* ,    (S38) 
where TVSU   is the SVD of i
T
XX ˆˆ 0  . The centroid and the covariance matrix of the 
“bootstrap” coordinates of each virus (extracted from *ˆ iX , 1001i ) are used to estimate 95% 
confidence regions for viral coordinates. 
 
Part 3. Effective dimensionality and recovery of titers 
3.1. Factors that may affect the effective dimensionality of titers 
Let TVSUH   be the SVD of an nm  table H of log-transformed titers. Recall that 
the columns of U (V) are called eigenvectors, and the diagonal entries of S are the n singular 
values of H, nii ,,1,  , sorted in decreasing order of magnitude. The rank (or dimensionality) 
of H is the number of its non-zero singular values. When all the n singular values are non-zero, H 
is said to be of full rank. If the rank of H is nr   and its entries are not contaminated by noise, 
then only the first r  „s will be non-zero. However, if the entries are contaminated by noise, 
then some of the other n-r  „s can also be non-zero. In this case, it is necessary to distinguish 
the  „s that are non-zero due to the “natural” variation of the data and those that are non-zero 
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due to noise. A number of statistical methods have been developed to address this problem. 
Among the most popular of these are methods that make certain assumptions about the 
distribution of  2i , ni ,,1 , the eigenvalues of HH
T
 [47]; each eigenvalue is said to 
represent the amount of variation explained by its corresponding eigenvector [47]. Common 
assumptions made by those methods include: (i) the noise contaminating the entries of H is 
normally distributed, as are the eigenvalues, and (ii) the noise-associated eigenvalues are 
significantly smaller than the other eigenvalues, since the latter eigenvalues reflect contributions 
from both noise and the natural variation of the data. Based on these assumptions, the “true” non-
zero eigenvalues can be identified by determining whether each eigenvalue is significantly 
greater than the mean of the eigenvalues smaller than it. This can be done by finding the 
maximum value of r for which: 
 
 
   


 

1,1
1
2
2
rnn
ri i
r frn ,        (S39) 
where rnf ,1  denotes the inverse cumulative function of the F-distribution with 1 and n-r degrees 
of freedom, and   is the level of statistical significance of the test. The above method for 
determining the effective rank, commonly called Malinowski‟s F-test, was developed by using 
Fisher‟s variance-ratio test [47]. An equivalent method was also developed by Carey et al. [48] 
by using a different approach. Note that (S39) is equivalent to Eqn. (3) of the main text. 
 Note that a number of different factors can cause variation in estimates of the effective 
dimensionality of titers. Some of those factors are discussed below. 
First, possible biological bases of the dimensions of titers are considered. The dimensions 
of titers may represent independent attributes of viruses and sera that determine the outcomes of 
the biophysical interactions that take place during the HI assay (see Part 1 for details on these 
interactions). In particular, the variation in titers arises from, among other factors, variation in 
viral attributes such as the affinity for red cell and susceptibility to antibody-mediated 
neutralization, and from attributes of sera such as the concentration of antibodies and the affinity 
of those antibodies for virus. Some of these attributes may vary independently of others and they 
may therefore form distinct dimensions of titers. Regardless of the specific nature of the 
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attributes that constitute the individual dimensions of titers, the relative contributions of those 
attributes to the variation in titers can have an important influence on the effective 
dimensionality. In particular, if the variation due to some attributes is substantially greater than 
the variation due to others, then the effective dimensionality can be lower than the actual 
dimensionality depending on the number of those “dominant” attributes. Moreover, if the 
contribution of the different attributes to variation in titers depends on the particular viruses and 
sera used in a given experiment, then this may cause the effective dimensionality of titers from 
independent experiments to also vary. 
Another factor that can affect the effective dimensionality of a given table of log-
transformed titers H is the way that the titers are processed. Consider, for example, the titer-
normalization procedure of [1]. Mathematically, that procedure can be expressed as: 
vHH

1
~
 ,           (S40) 
where H
~
 is an nm  matrix of normalized titers, 1

 an 1m  vector of ones, and v

 a n1  vector 
whose entries are the maximum values found in each of the n rows of H. If H is of rank r, then it 
can be written as the product of two matrices each of rank r: PQH  , where P has dimensions 
rm  and Q has dimensions nr   [49]. Therefore, H
~
 can be rewritten as: 
  






v
Q
PH 

1
~
.          (S41) 
If 1

 does not belong to the column space of P, then the matrix  1

P  will be of rank r+1 (e.g., 
see [48]). Similarly, if v

 does not belong to the row space of Q, then 





v
Q
  will be of rank r+1. 
Therefore, titer normalization will increase the rank of H by 1 if both of the above conditions 
hold, since [49]: 
    
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~
.        (S42) 
In addition, the rank of a table of titers can increase when titers from different 
experiments are combined. For example, consider the case when titers for m viruses are 
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measured in two experiments, the first involving n1 sera and the second involving n2 sera. Denote 
by H1 (H2) the table of titers obtained from the first (second) experiment. The dimensions of H1 
and H2 will be 1nm  and 2nm , respectively. We are interested in determining the rank of the 
 21 nnm   composite table  21,HHC  , consisting of titers measured in the two experiments. 
It is well known that the rank of C is given by [49]: 
              2111121111 ,min, HHHIrHrHrHHHIHrHrCr   ,   (S43) 
where 

1H  is the generalized inverse of H1 and I is the identity matrix. 

1H can be obtained from 
the SVD of H1, 
TUSVH 1 , as follows: 
TTUSVH ˆ1 

, where Sˆ  is obtained from S by replacing 
each non-zero diagonal entry by its reciprocal. It follows from (S43) that the rank of C will be 
greater than that of H1 if   211 HHHI   does not have a rank of 0. Moreover, if the rank of H1 is 
greater than 1, then the rank of C will also be greater than 1 irrespective of the rank of H2. This is 
also true for an arbitrary number s of tables of titers measured for the same m viruses; to see this, 
simply partition the tables into two sub-tables, H1 and  sHH ,,2  . The above statement is also 
true if H2 contains titers for an additional m2 viruses that are different from the m viruses found 
in H1. In this case, C can be written as: 



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


 2
1
H
H
C ,          (S44) 
where  is a matrix of zeros.  , C, and H2 have dimensions 12 nm  ,    212 nnmm  , and 
  12 nmm  , respectively. Following the same approach used above, the rank of C can be 
expressed as: 
      2111121111 ,, HHHIHrHrH
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where we have used the fact that [49]: 
 




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


1
1
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H
.          (S47) 
Eqn. (S45) is identical to (S43); the conclusions reached above also apply here. 
 
3.2. Nuclear-norm minimization for the recovery of unmeasured titers 
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Given an nm  table H consisting of log-transformed titers, titers missing from the table 
(“unmeasured” titers) are recovered by finding an nm  matrix X that minimizes: 
 



ijH
ijij XHX
2
 ,         (S48) 
where   and   are regularizing constants and 

X  denotes the nuclear norm of X, the sum of 
the singular values of X. This optimization problem was solved using the fixed point 
continuation (FPC) algorithm of Ma et al. [50], with default parameters and two minor 
modifications. Firstly, the algorithm was modified to use exact SVD rather than the approximate 
SVD implemented in the original algorithm. This is because the dimensions of the tables of 
empirical titers analyzed in this study were small enough that exact SVD of those tables was 
computationally very efficient. Secondly, the algorithm was modified to allow the minimization 
of only the r largest singular values of X (rather than 

X ) in cases when r is known. Note that 
in the FPC algorithm, η is set to a theoretically motivated value of ½ [50], whereas an initial 
value of μ is chosen to accord 

X  a similar weight as the second sum of (S48). The chosen 
value of μ is then iteratively decreased. The Matlab code used in this study is available upon 
request. It will eventually be incorporated into software for analyzing serological data that will 
be made freely available to the public. 
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Table S1. List of tables of empirical titers analyzed in this study 
H308001, H307002, H305002, H304001, H302001, H302002, H301001, H301002, 
H301003, H300002, H30003, H300004, H399001, H399002, H387001, H375001,  
H369001, H108001, H107001, H104001, B001001, B001002, B001003, B000001 
The listed tables are a subset of the tables published in Supplement A of [38], which only contain known 
titers -- titers that occur in the interval (10 to 10240). Because it was of interest to compute the first five 
singular values of each table, only tables containing at least five columns are listed. 
 
 
